Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatchewan, Canada.
Vaccine. 2010 Jan 22;28(4):981-8. doi: 10.1016/j.vaccine.2009.10.134. Epub 2009 Nov 17.
Transmissible spongiform encephalopathies (TSEs) depend on misfolding of a normal cellular protein (PrP(C)) to an infectious conformation (PrP(Sc)). Targeting PrP(Sc) may represent an effective strategy for immunotherapy while avoiding consequences associated with immune responses to self-proteins. A weakly immunogenic epitope of PrP(C) (YYR), which induces PrP(Sc)-specific antibodies, is used as a starting point for vaccine development. Through optimization of epitope, as well as formulation/delivery, we enhance immunogenicity while retaining PrP(Sc) specificity. In particular, QVYYRPVDQYSNQN, presented by a leukotoxin carrier protein, emerges as a strong vaccine candidate. A vaccine representing this construct induces consistent and sustained serum PrP(Sc)-specific IgG antibody responses following two vaccinations. Antigen specific antibodies are also present within cerebral spinal fluid and mucosal secretions. These characteristics provide a foundation for development of a TSE vaccine.
传染性海绵状脑病(TSEs)依赖于正常细胞蛋白(PrP(C))错误折叠成感染性构象(PrP(Sc))。靶向 PrP(Sc)可能代表一种有效的免疫治疗策略,同时避免与针对自身蛋白的免疫反应相关的后果。PrP(C) 的一个弱免疫原性表位(YYR)诱导 PrP(Sc)-特异性抗体,可用作疫苗开发的起点。通过优化表位以及配方/递送,我们在保留 PrP(Sc)特异性的同时增强了免疫原性。具体来说,由白细胞毒素载体蛋白呈递的 QVYYRPVDQYSNQN 作为一种强有力的疫苗候选物出现。该构建体的疫苗在两次接种后诱导一致且持续的血清 PrP(Sc)-特异性 IgG 抗体反应。抗原特异性抗体也存在于脑脊髓液和粘膜分泌物中。这些特征为 TSE 疫苗的开发提供了基础。